Epratuzumab Biosimilar - Research Grade

Human

CD22

5mg/ml

Human IgG1 Kappa

CHO Cells

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Functional Assays

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Detects human CD22

Blue ice

CD22 is an inhibitory sialic-acid-binding receptor on B cells that tunes B-cell receptor signalling, a recurring target in B-cell malignancy research. This recombinant anti-human CD22 monoclonal is an unconjugated, non-therapeutic analog of epratuzumab, intended for research use only (RUO). It is produced to in vivo standards with low endotoxin and supplied in scalable milligram (mg) to gram (g) quantities for heavy-usage and high-throughput laboratories. Researchers apply it in functional assays, B-cell signalling and internalisation studies, defined controls, and in vivo models of B-lineage disease, relying on reproducible lot-to-lot behaviour for large experimental campaigns.

CAT-8015,GCR-8015,HA22,(sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14

P20273

ICH3002

https://www.imgt.org/mAb-DB/